Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
PSG conducted a comprehensive survey of over 200 healthcare payers, including health plans and employers, to better understand their perspectives on the use of GLP-1s for treatment of obesity
In diabetic kidney disease, demonstrably slows disease progression
For women with existing thyroid conditions, such as hypothyroidism managed with levothyroxine, GLP-1 medications dont directly interact with thyroid hormone replacement
Only a licensed provider can determine whether GLP-1 treatment is clinically appropriate for an individual patient
Modified metabolic responsiveness to glucagon in cold-acclimated and heat-acclimated rats
Potential future developments include novel delivery mechanisms, multi-receptor agonists, and a broader range of therapeutic uses for the treatment of metabolic disorders and their consequences
US$ 26.46
US$ 23.62
US$ 24.84
US$ 20.27
US$ 26.09
US$ 22.58
US$ 29.31
